K. M. Andrews

发表

(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.

Zhengrong Zhao, Dennis E Danley, M. Ammirati, 2007, Bioorganic & medicinal chemistry letters.

cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.

M. Ammirati, D. Danley, S. Wright, 2006, Journal of medicinal chemistry.

Suppression of insulin-stimulated glucose transport in L6 myocytes by calcitonin gene-related peptide.

S. Oreña, D. Kreutter, K. M. Andrews, 1989, Biochemical and biophysical research communications.

(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.

M. Ammirati, D. Danley, R. McPherson, 2009, Bioorganic & Medicinal Chemistry Letters.

1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.

R. McPherson, J. Treadway, D. Beebe, 2011, Bioorganic & medicinal chemistry letters.

Possibility of Distinct Insulin-Signaling Pathways Beyond Phosphatidylinositol 3-Kinase–Mediating Glucose Transport and Lipogenesis

E. M. Gibbs, R. W. Stevenson, D. Kreutter, 1998, Diabetes.

The Antihyperglycemic Agent Englitazone Prevents the Defect in Glucose Transport in Rats Fed a High-Fat Diet

R. McPherson, E. M. Gibbs, A. Swick, 1996, Diabetes.

Discovery of triazolopyrimidine-based PDE8B inhibitors: exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes.

S. Wright, K. Houseknecht, W. Esler, 2012, Bioorganic & medicinal chemistry letters.

Insulinlike Activity of New Antidiabetic Agent CP 68722 in 3T3-L1 Adipocytes

E. M. Gibbs, R. W. Stevenson, D. Kreutter, 1990, Diabetes.

Glucagon-like peptide-1 and analogs: A structure/function analysis

J. Withka, D. Singleton, W. Massefski, 2002 .

Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes.

Carolyn B Levy, R. McPherson, J. Treadway, 2000, Diabetes.

Glycemic control in mice with targeted disruption of the glucagon receptor gene.

J. Stock, J. Mcneish, M. Allen, 2002, Biochemical and biophysical research communications.

New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors.

Michael G. Lopaze, J. Parker, Shawn Cabral, 2005, Bioorganic & medicinal chemistry letters.

Comparison of the glucose dependency of glucagon-like peptide-1 (7-37) and glyburide in vitro and in vivo.

D. Hargrove, N. A. Nardone, R. W. Stevenson, 1996, Metabolism: clinical and experimental.

Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III.

D. Hargrove, N. A. Nardone, J. Parker, 1997, Biochemical and biophysical research communications.

Structure-function analysis of a series of glucagon-like peptide-1 analogs.

D. Singleton, W. Massefski, R. W. Stevenson, 2009, The journal of peptide research : official journal of the American Peptide Society.

Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: contributions of types III and IV to the modulation of insulin secretion.

K. Brayman, J. Parker, R. Ketchum, 1995, Biochemical and biophysical research communications.

(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.

M. Ammirati, D. Danley, R. McPherson, 2009, Bioorganic & medicinal chemistry letters.